Frequently Asked Questions
GHK-Cu is a naturally occurring copper-binding tripeptide glycyl-L-histidyl-L-lysine bound to a copper(II) ion. First isolated from human plasma in 1973, it has been studied for over five decades and is one of the most extensively researched peptides in regenerative and cellular biology.
No. GHK-Cu is not approved by the MHRA (UK), FDA (US), or any other regulatory authority for human or veterinary use as a therapeutic compound. Aeternum supplies GHK-Cu research material exclusively for research purposes.
Not for human consumption.
Most research peptides act through a single mechanism. GHK-Cu is studied as a compound operating across three: copper delivery to copper-dependent enzymes, receptor-level signaling through pathways including TGF-β and PI3K/Akt, and broad modulation of gene expression. This multi-mechanism profile is unusual for a molecule of its size and is why it remains a model compound in modern peptide research.
Reach. Most peptides bind one receptor and trigger one downstream effect. GHK-Cu is studied as a compound that operates at three levels simultaneously, delivering copper to enzyme systems, engaging cell-surface signaling pathways, and modulating gene expression across thousands of human genes. This breadth of mechanism is what distinguishes it within peptide science. No. GHK-Cu supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice. GHK-Cu is studied across an unusually broad range of scientific disciplines. Active areas of investigation include connective tissue biology, antioxidant enzyme support, fibroblast signaling, transcriptional regulation, inflammatory pathways, and mitochondrial function.
No. GHK-Cu supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice.
GHK-Cu is studied across an unusually broad range of scientific disciplines. Active areas of investigation include connective tissue biology, antioxidant enzyme support, fibroblast signaling, transcriptional regulation, inflammatory pathways, and mitochondrial function.
The blend pairs two distinct synthetic peptides: BPC-157, a 15-amino-acid pentadecapeptide originally identified in human gastric juice, and TB-500, a synthetic fragment of the naturally occurring protein thymosin beta-4. Each is among the most extensively studied peptides in modern regenerative research, and together they are studied as a complementary pairing engaging two non-overlapping pathways.
No. The blend is not approved by the MHRA (UK), FDA (USA), or any other regulatory authority for human or veterinary use. Aeternum supplies this blend exclusively for research purposes.
Not for human consumption.
Because their mechanisms are complementary rather than overlapping. BPC-157 is studied for its role in angiogenic signalling - the formation of new blood vessels - and growth factor expression. TB-500 is studied for its role in G-actin sequestration and cellular migration. One engages the signalling environment; the other engages the structural machinery of cellular movement. This is the scientific rationale for examining them as a blend.
Architecture. A single peptide engages one mechanism. This blend engages two through different cellular systems, with different downstream effects. BPC-157 contributes to angiogenic and growth factor signalling; TB-500 contributes to actin-mediated cellular migration. Together, they engage stages of the regenerative cascade that neither peptide engages alone.
No. The blend supplied by Aeternum is intended strictly for lab research purposes by trained professionals only. We do not provide dosage recommendations, administration guidance, or medical advice.
Active areas of investigation include angiogenic signalling, cytoskeletal organization, cellular migration, growth factor expression, nitric oxide modulation, and extracellular matrix remodelling. These pathways are studied independently for each peptide and in combination as part of broader regenerative peptide research.
GLP-3 is an investigational peptide and one of the most studied compounds in modern metabolic research. It is classified as a triple agonist, a single molecule designed to engage three metabolic receptors at once: GLP-1, GIP, and glucagon. Together, these receptors form three of the central signalling axes in metabolic regulation.
No. GHK-Cu is not approved by the MHRA (UK), FDA (US), or any other regulatory authority for human or veterinary use as a therapeutic compound. Aeternum supplies GHK-Cu research material exclusively for research purposes.
Not for human consumption.
Most metabolic peptides act on one or two receptors. GLP-3 is the first compound designed to engage three. The addition of glucagon receptor activity, distinct from the two incretin pathways, is the defining feature, bringing a third axis of metabolic signalling into the same molecule.
Reach. Earlier metabolic peptides engage one or two hormone pathways. GLP-3 engages three GLP-1, GIP, and glucagon within a single molecule.
The glucagon receptor is the differentiator, bringing energy substrate signalling into a mechanism that already covers the two incretin pathways. No. GLP-3 supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice. GLP-3 is designed in California and sourced in Great Britain. Each batch is produced across two of the world's most rigorous research environments and undergoes independent third-party purity testing.
No. GLP-3 supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice.
GLP-3 is designed in California and sourced in Great Britain. Each batch is produced across two of the world's most rigorous research environments and undergoes independent third-party purity testing.
NAD+, nicotinamide adenine dinucleotide, is a naturally occurring coenzyme found in every living cell. It is one of the most extensively studied molecules in cellular biology, participating in hundreds of enzymatic reactions across energy metabolism, gene regulation, and DNA repair.
No. NAD+ is not approved by the MHRA (UK), FDA (US), or any other regulatory authority for human or veterinary use as a therapeutic compound. Aeternum supplies NAD+ research material exclusively for research purposes.
Most cellular molecules serve a single role. NAD+ serves three functions: it acts as an electron carrier in energy metabolism, as the required substrate for the sirtuin enzyme family, and as the required substrate for PARP enzymes in DNA repair. This breadth of function is why NAD+ remains a central focus of modern longevity-led research.
No. NAD+ is a dinucleotide coenzyme, not a peptide. It is composed of two linked nucleotides, one containing adenine, the other nicotinamide. NAD+ is grouped within peptide research catalogues because it is studied alongside peptides in cellular optimization and longevity research, but its molecular classification is distinct.
No. NAD+ supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice.
NAD+ is studied across one of the broadest research landscapes in cellular biology. Active areas of investigation include mitochondrial function, sirtuin biology, DNA repair, NAD+ consumption dynamics (including the role of CD38), and the redox chemistry that underlies metabolic regulation.
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) - the hypothalamic peptide responsible for stimulating growth hormone release from the pituitary. Structurally, it preserves the full GHRH sequence with an N-terminal trans-3-hexenoic acid modification that increases its resistance to enzymatic breakdown.
No. The active molecule has FDA approval as a prescription pharmaceutical for a specific clinical indication, but that approval does not extend to research-grade material supplied for laboratory investigation. Aeternum supplies Tesamorelin strictly for research purposes.
Not for human consumption.
Tesamorelin is the only synthetic GHRH analogue with current FDA approval. The active molecule was first approved in 2010 and re-approved in an updated formulation in 2025 as a prescription pharmaceutical. This makes it the most extensively characterized molecule in its class with established pharmacokinetics, a documented safety profile, and decades of published clinical literature.
Mechanism level. Many growth hormone secretagogues act downstream of the pituitary, bypassing the body's natural regulatory system. Tesamorelin acts at the receptor itself, binding the same pituitary GHRH receptor that responds to endogenous hypothalamic GHRH. This preserves the pulsatile rhythm in which the body naturally releases growth hormone, rather than producing a flat, sustained elevation.
No. Tesamorelin supplied by Aeternum is intended strictly for research purposes only. We do not provide dosage recommendations, administration guidance, or medical advice.
Tesamorelin is studied across a broad range of endocrine and metabolic research areas. Active investigation includes GHRH receptor pharmacology, pulsatile growth hormone signalling, the GH–IGF-1 axis, hypothalamic-pituitary regulation, hepatic substrate metabolism, and the role of the GH–IGF-1 system in longevity research.
